Back to Search
Start Over
Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
- Source :
-
Gynecologic oncology [Gynecol Oncol] 2019 May; Vol. 153 (2), pp. 213-214. - Publication Year :
- 2019
- Subjects :
- Antineoplastic Agents, Immunological pharmacology
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols pharmacology
BRCA1 Protein genetics
BRCA2 Protein genetics
Clinical Trials as Topic
Female
Humans
Mutation
Ovarian Neoplasms genetics
Ovarian Neoplasms immunology
Poly(ADP-ribose) Polymerase Inhibitors pharmacology
Poly(ADP-ribose) Polymerase Inhibitors therapeutic use
Programmed Cell Death 1 Receptor antagonists & inhibitors
Programmed Cell Death 1 Receptor immunology
Recombinational DNA Repair drug effects
Recombinational DNA Repair immunology
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Immunotherapy methods
Lymphocytes, Tumor-Infiltrating immunology
Ovarian Neoplasms drug therapy
Recombinational DNA Repair genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1095-6859
- Volume :
- 153
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Gynecologic oncology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 31027611
- Full Text :
- https://doi.org/10.1016/j.ygyno.2019.04.014